# The interplay of dietary sugar, chronic inflammation, and bladder cancer: mechanistic insights, evidence, and prevention strategies

**Authors:** Larisa Tratnjek, Aleksandar Janev, Tadeja Kuret, Urška Dragin Jerman

PMC · DOI: 10.3389/fimmu.2026.1731784 · Frontiers in Immunology · 2026-02-09

## TL;DR

This paper explores how high sugar diets contribute to bladder cancer through inflammation and gut microbiota changes, and suggests lifestyle changes for prevention.

## Contribution

The paper provides a comprehensive review of the mechanisms linking dietary sugar, inflammation, and bladder cancer, highlighting novel preventive strategies.

## Key findings

- High dietary sugar intake is linked to systemic inflammation and bladder cancer risk through mechanisms like AGEs and inflammatory pathways.
- Diabetes is consistently associated with increased bladder cancer incidence and worse outcomes.
- Modifying diet and lifestyle can help regulate blood sugar and reduce bladder cancer risk.

## Abstract

High dietary sugar intake has emerged as a key modulator of systemic inflammation and metabolic dysregulation, both of which are associated with an increased risk of several chronic diseases, including cancer. Although bladder cancer is primarily driven by factors such as smoking and occupational exposures, metabolic dysregulation may also play a contributory role. Experimental studies indicate that elevated glucose levels promote proliferation, epithelial-mesenchymal transition, increase invasion, and reduce autophagy in bladder cancer cells. Epidemiological evidence suggests associations of high dietary glycaemic index/load and high sugar consumption with bladder cancer risk, although findings for these dietary factors remain heterogeneous. Furthermore, epidemiological data consistently demonstrate a positive association between diabetes mellitus and increased bladder cancer incidence and adverse clinical outcomes. Mechanistically, hyperglycaemia and accumulation of advanced glycation end products (AGEs) can activate inflammatory signalling pathways, including NF-κB, MAPK, and the NLRP3 inflammasome, leading to increased cytokine production, immune dysregulation, and oxidative stress. High dietary sugar intake has also been shown to alter gut microbiota composition, typically reducing short-chain fatty acid (SCFA)-producing bacteria and promoting intestinal permeability, endotoxaemia, and sustained immune activation through TLR4-dependent pathways. Within the bladder tumour microenvironment, systemic inflammatory disturbances enhance oncogenic signalling cascades such as COX-2, JAK/STAT3, and NF-κB, thereby fostering epithelial-mesenchymal transition, angiogenesis, and potential resistance to therapy. Evidence suggests that maintaining well-regulated blood sugar levels may help lower the risk of bladder cancer. Adopting lifestyle habits such as whole-food, fibre-rich diets, probiotics, and regular physical activity supports metabolic and microbial homeostasis, SCFA-mediated immune regulation, and inflammation reduction, thereby serving as a preventive strategy. This review aims to synthesise current evidence on the complex interplay between dietary sugar intake, gut microbiota dysregulation, systemic inflammation, and bladder cancer, and to highlight potential preventive dietary interventions.

## Linked entities

- **Proteins:** NFKB1 (nuclear factor kappa B subunit 1), MAPK (mitogen activated kinase-like protein), NLRP3 (NLR family pyrin domain containing 3), COX2 (cytochrome c oxidase subunit II), TLR4 (toll like receptor 4)
- **Diseases:** bladder cancer (MONDO:0004986), diabetes mellitus (MONDO:0005015)

## Full-text entities

- **Genes:** Prkaa2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 78975] {aka Ampk, Ampka2}, ELANE (elastase, neutrophil expressed) [NCBI Gene 1991] {aka ELA2, GE, HLE, HNE, NE, PMN-E}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, RENBP (renin binding protein) [NCBI Gene 5973] {aka RBP, RNBP}, RNF183 (ring finger protein 183) [NCBI Gene 138065], Yap1 (yes-associated protein 1) [NCBI Gene 22601] {aka Yap, Yap65, Yki, Yorkie}, UCA1 (urothelial cancer associated 1) [NCBI Gene 652995] {aka CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, Gdf15 (growth differentiation factor 15) [NCBI Gene 23886] {aka MIC-1, NAG-1, SBF}, ITGAX (integrin subunit alpha X) [NCBI Gene 3687] {aka CD11C, SLEB6}, WNT5A (Wnt family member 5A) [NCBI Gene 7474] {aka hWNT5A}, SNAI1 (snail family transcriptional repressor 1) [NCBI Gene 6615] {aka SLUGH2, SNA, SNAH, SNAIL, SNAIL1, dJ710H13.1}, Pkm (pyruvate kinase, muscle) [NCBI Gene 18746] {aka Pk-2, Pk-3, Pk3, Pkm2}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, Tafazzin (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 66826] {aka 5031411C02Rik, 9130012G04Rik, G4.5, Taz}, TXNIP (thioredoxin interacting protein) [NCBI Gene 10628] {aka ARRDC6, EST01027, HHCPA78, THIF, VDUP1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, AKR1B1 (aldo-keto reductase family 1 member B) [NCBI Gene 231] {aka ADR, ALDR1, ALR2, AR}, TRAF6 (TNF receptor associated factor 6) [NCBI Gene 7189] {aka MGC:3310, RNF85}, TIRAP (TIR domain containing adaptor protein) [NCBI Gene 114609] {aka BACTS1, Mal, MyD88-2, wyatt}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, Gpbar1 (G protein-coupled bile acid receptor 1) [NCBI Gene 338443] {aka M-BAR, Tgr5}, ARG1 (arginase 1) [NCBI Gene 383], NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, MAP3K7 (mitogen-activated protein kinase kinase kinase 7) [NCBI Gene 6885] {aka CSCF, FMD2, MEKK7, TAK1, TGF1a}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, Pkm (pyruvate kinase M1/2) [NCBI Gene 25630] {aka PK, PKM12, Pk3, Pkm2}, SLC2A2 (solute carrier family 2 member 2) [NCBI Gene 6514] {aka GLUT2}, KHK (ketohexokinase) [NCBI Gene 3795] {aka FRUCTU}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, HK2 (hexokinase 2) [NCBI Gene 3099] {aka HKII, HXK2}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, IL1R1 (interleukin 1 receptor type 1) [NCBI Gene 3554] {aka CD121A, CRMO3, D2S1473, IL-1R-alpha, IL-1RT1, IL1R}, SORD (sorbitol dehydrogenase) [NCBI Gene 6652] {aka HEL-S-95n, HMNR8, RDH, SDH, SORD1, SORDD}, TICAM1 (TIR domain containing adaptor molecule 1) [NCBI Gene 148022] {aka IIAE6, MyD88-3, PRVTIRB, TICAM-1, TRIF}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, HCAR2 (hydroxycarboxylic acid receptor 2) [NCBI Gene 338442] {aka GPR109A, HCA2, HM74a, HM74b, NIACR1, PUMAG}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, RIPK2 (receptor interacting serine/threonine kinase 2) [NCBI Gene 8767] {aka CARD3, CARDIAK, CCK, GIG30, RICK, RIP2}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, CCL18 (C-C motif chemokine ligand 18) [NCBI Gene 6362] {aka AMAC-1, AMAC1, CKb7, DC-CK1, DCCK1, MIP-4}, Gdf15 (growth differentiation factor 15) [NCBI Gene 29455], SLC2A3 (solute carrier family 2 member 3) [NCBI Gene 6515] {aka GLUT3}, CDH2 (cadherin 2) [NCBI Gene 1000] {aka ACOGS, ADHD8, ARVD14, CD325, CDHN, CDw325}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, GSR (glutathione-disulfide reductase) [NCBI Gene 2936] {aka CNSHA10, GR, GSRD, HEL-75, HEL-S-122m}, IRF3 (interferon regulatory factor 3) [NCBI Gene 3661] {aka IIAE7}, OCLN (occludin) [NCBI Gene 100506658] {aka BLCPMG, PPP1R115, PTORCH1}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, S100A1 (S100 calcium binding protein A1) [NCBI Gene 6271] {aka S100, S100-alpha, S100A}, GDF15 (growth differentiation factor 15) [NCBI Gene 9518] {aka GDF-15, HG, MIC-1, MIC1, NAG-1, PDF}, Igf1 (insulin-like growth factor 1) [NCBI Gene 24482] {aka IGF}, Crp (C-reactive protein) [NCBI Gene 25419] {aka Aa1249, Ab1-341, Ab2-196, Ac1-114, Ac1262, Ac2-069}
- **Diseases:** systemic (MESH:D015619), PLCO (MESH:D010051), bladder carcinogenesis (MESH:D063646), T2DM (MESH:D003924), adipose (MESH:D018205), obesity (MESH:D009765), NK (MESH:D000077428), Bladder cancer (MESH:D001749), chronic (MESH:D002908), papillary tumours (MESH:D002291), Chronic cystitis (MESH:D003556), Immune dysregulation (OMIM:614878), metabolic dysregulation (MESH:D021081), metabolic disorders (MESH:D008659), bladder irritation (MESH:D001745), tumorigenic (MESH:D002471), Mortality (MESH:D003643), carcinogenic (MESH:D011230), colorectal cancer (MESH:D015179), Mitochondrial dysfunction (MESH:D028361), GI (MESH:C566784), Chronic systemic inflammation (MESH:D007249), endotoxemia (MESH:D019446), TNM (MESH:D009362), metabolic syndrome (MESH:D024821), NMIBC (MESH:D000093284), UTIs (MESH:D014552), insulin resistance (MESH:D007333), infection (MESH:D007239), Diabetes Mellitus (MESH:D003920), dysbiosis (MESH:D064806), carcinoma in situ (MESH:D002278), Cancer (MESH:D009369)
- **Chemicals:** refined sugar (MESH:D019422), LPS (MESH:D008070), lipid (MESH:D008055), nucleotide (MESH:D009711), 3-phosphoglycerate (MESH:C005156), sucrose (MESH:D013395), Dietary sugar (MESH:D000073417), coenzyme Q (MESH:D014451), STZ (MESH:D013311), Fructose (MESH:D005632), Sorbitol (MESH:D013012), m6A (MESH:C005955), polyphenols (MESH:D059808), ATP (MESH:D000255), AGEs (MESH:D017127), Metformin (MESH:D008687), omega-6 fatty acids (MESH:D043371), glutathione (MESH:D005978), carotenoids (MESH:D002338), luminal (MESH:D010634), phosphoenolpyruvate (MESH:D010728), peroxynitrite (MESH:D030421), Glucose (MESH:D005947), glucosamine (MESH:D005944), 8-OHdG (MESH:D000080242), blood glucose (MESH:D001786), hydroxyl radicals (MESH:D017665), SCFA (MESH:D005232), galactose (MESH:D005690), hydroxytyrosol (MESH:C005975), ROS (MESH:D017382), FADH2 (MESH:C058805), acetate (MESH:D000085), NAD+ (MESH:D009243), oleuropein (MESH:C002769), alcohol (MESH:D000438), tryptophan (MESH:D014364), acetic acid (MESH:D019342), RNS (MESH:D011886), indole-3-aldehyde (MESH:C012381), Sugar (MESH:D000073893), acid (MESH:D000143), salt (MESH:D012492), oxygen (MESH:D010100), Caffeic Acid Phenethyl Ester (MESH:C055494), Superoxide (MESH:D013481), BBN (-), hydrogen peroxide (MESH:D006861), pyruvate (MESH:D019289), fat (MESH:D005223), Olive oil (MESH:D000069463), nitrosourea (MESH:D009607), Shikonin (MESH:C016101), Bile acids (MESH:D001647), hydrogen sulphide (MESH:D006862), MDP (MESH:D000119), TCA (MESH:D014238), 2-Deoxy-D-Glucose (MESH:D003847), fructose-1-phosphate (MESH:C032284), ADP (MESH:D000244)
- **Species:** gut metagenome (species) [taxon 749906], Gallus gallus (bantam, species) [taxon 9031], Escherichia coli (E. coli, species) [taxon 562], Bacillus sp. CG (species) [taxon 1196795], Lacticaseibacillus casei (species) [taxon 1582], Bilophila (genus) [taxon 35832], Schistosoma haematobium (species) [taxon 6185], Mycobacterium tuberculosis variant bovis BCG (no rank) [taxon 33892], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12926174/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12926174/full.md

## References

232 references — full list in the complete paper: https://tomesphere.com/paper/PMC12926174/full.md

---
Source: https://tomesphere.com/paper/PMC12926174